Phase I/Phase II Open Label Study of the TLR3 Agonist Poly-ICLC as an Adjuvant for NY-ESO-1 Protein Vaccination With or Without Montanide ISA-51 VG in Patients With High Risk Melanoma in Complete Clinical Remission
Phase of Trial: Phase I/II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Cancer vaccine NY-ESO-1 (Primary) ; Poly ICLC (Primary) ; Montanide ISA-51
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacogenomic
- 10 Jun 2017 Biomarkers information updated
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 07 Jan 2015 Status changed from not yet recruiting to completed according to ClinicalTrials.gov record.